Krystal Biotech, Inc.
$276.4
▲
1.37%
2026-04-22 10:12:13
www.krystalbio.com
NMS: KRYS
Explore Krystal Biotech, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$8.11 B
Current Price
$276.4
52W High / Low
$298.3 / $122.8
Stock P/E
40.42
Book Value
$41.78
Dividend Yield
—
ROCE
13.1%
ROE
18.91%
Face Value
—
EPS
$6.84
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
295
Beta
0.54
Debt / Equity
0.77
Current Ratio
9.95
Quick Ratio
9.56
Forward P/E
24.48
Price / Sales
19.59
Enterprise Value
$6.75 B
EV / EBITDA
41.45
EV / Revenue
17.35
Rating
Strong Buy
Target Price
$314
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Efficient use of capital employed.
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Strong operating margin profile.
- Net margin remains healthy.
Cons
- Valuation is rich on a P/E basis.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Tonix Pharmaceuticals Holding Corp. | $14.34 | — | $184.59 M | — | -49.81% | -64.48% | $69.97 / $11.6 | $19.17 |
| 2. | CorMedix Inc. | $7.58 | 3.58 | $584.18 M | — | 23.03% | 66.56% | $17.43 / $6.13 | $5.11 |
| 3. | Aktis Oncology, Inc. | $20.83 | — | $1.08 B | — | -31.96% | -29.45% | $29.16 / $14.72 | $-159.68 |
| 4. | Decoy Therapeutics Inc. | $5.89 | — | $3.09 M | — | -379.33% | -3.38% | $415.8 / $5.4 | $11.07 |
| 5. | Exicure, Inc. | $3.77 | — | $22.85 M | — | -99.65% | -92.47% | $12.65 / $3.1 | $0.62 |
| 6. | SeaStar Medical Holding Corporation | $4.63 | — | $16.77 M | — | -116.89% | -2.95% | $13.4 / $2.07 | $2.71 |
| 7. | Ultragenyx Pharmaceutical Inc. | $25.06 | — | $2.39 B | — | -46.6% | -6.08% | $42.37 / $18.29 | $-0.83 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 107.11 M | 97.8 M | 96.04 M | 88.18 M | 91.14 M | — |
| Operating Profit | 44.27 M | 41.37 M | 39.31 M | 36.18 M | 41.38 M | — |
| Net Profit | 51.4 M | 79.36 M | 38.33 M | 35.73 M | 45.48 M | — |
| EPS in Rs | 1.75 | 2.7 | 1.3 | 1.21 | 1.55 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 389.13 M | 290.51 M | 50.7 M | 0 M |
| Operating Profit | 161.29 M | 103.25 M | -97.12 M | -120.2 M |
| Net Profit | 204.83 M | 89.16 M | 10.93 M | -139.97 M |
| EPS in Rs | 6.96 | 3.03 | 0.37 | -4.76 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 1.33 B | 1.06 B | 818.36 M | 558.45 M |
| Total Liabilities | 114.23 M | 109.46 M | 39.71 M | 36.22 M |
| Equity | 1.22 B | 946.38 M | 778.64 M | 522.23 M |
| Current Assets | 1.02 B | 742.04 M | 587.91 M | 383.78 M |
| Current Liabilities | 102.94 M | 102 M | 33.09 M | 28.85 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 200.87 M | 123.42 M | -88.8 M | -100.57 M |
| Investing CF | -58.42 M | -163.44 M | 82.64 M | -114.08 M |
| Financing CF | 8.71 M | 27.01 M | 202.75 M | 35.35 M |
| Free CF | 188.91 M | 119.18 M | -100.6 M | -153.55 M |
| Capex | -11.95 M | -4.24 M | -11.8 M | -52.98 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 473.02% | — | — | — |
| Earnings Growth % | 715.58% | 107.81% | — | — |
| Profit Margin % | 30.69% | 21.56% | — | — |
| Operating Margin % | 35.54% | -191.56% | — | — |
| Gross Margin % | 93.09% | 93.9% | — | — |
| EBITDA Margin % | 37.85% | -179.9% | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.